SCHEMBL1406076

SCHEMBL1406076

COC(=O)c1sc(Br)cc1NC(N)=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 2/20 0.47
LMNA P02545 1/20 0.47
IKBKB O14920 4/20 0.46
HPGD P15428 2/20 0.45
MAPK14 Q16539 3/20 0.44
RAF1 P04049 3/20 0.43
MAPK13 O15264 1/20 0.43
MAPK12 P53778 1/20 0.43
MAPK11 Q15759 1/20 0.43
HTT P42858 1/20 0.42
ATM Q13315 1/20 0.42
PPARG P37231 1/20 0.42
NCOA1 Q15788 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
TP53 P04637 2/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21411362 0.85 ALDH1A1 (0.58) MAPTKDM4EALDH1A1LMNAHPGD
SCHEMBL612156 0.83 MAPT (0.42) MAPTKDM4EALDH1A1LMNAHPGD
SCHEMBL490588 0.83 IKBKB (0.57) IKBKB
SCHEMBL5463033 0.82 MAPK14 (0.48) MAPTKDM4EALDH1A1LMNAIKBKB
SCHEMBL16267991 0.81 IKBKB (0.61) ALDH1A1IKBKBHPGDMAPK14RAF1
SCHEMBL612016 0.80 MAPK14 (0.41) MAPTKDM4EALDH1A1LMNAHPGD
SCHEMBL26189260 0.80 RAF1 (0.41) MAPTKDM4EALDH1A1LMNAHPGD
SCHEMBL101455 0.79 RAF1 (0.42) MAPTKDM4EALDH1A1LMNAMAPK14
SCHEMBL27192028 0.79 ALDH1A1 (0.54) MAPTKDM4EALDH1A1LMNAHPGD
SCHEMBL669321 0.77 RAF1 (0.39) MAPTKDM4EALDH1A1LMNAIKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025262243-A1 THIENO- AND THIAZOLOPYRIMIDINE-2,6-DIONES AND USE THEREOF AS IMMUNOMODULATORS INVIOS GMBH (AT) 2025-12-26 WO disclosed
US-20250009723-A1 MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE FIMBRION THERAPEUTICS, INC. 2025-01-09 US disclosed
EP-3003322-B1 MANNOSE DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS WASHINGTON UNIVERSITY ST LOUIS (US) 2023-09-13 EP disclosed
EP-3003322-B1 MANNOSE DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS WASHINGTON UNIVERSITY ST LOUIS (US) 2023-09-13 EP disclosed
WO-2023056951-A1 ARYL-SUBSTITUTED HETEROCYCLIC COMPOUND 杭州德睿智药科技有限公司 2023-04-13 WO disclosed
US-20230033327-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS WASHINGTON UNIVERSITY 2023-02-02 US disclosed
US-20220235087-A1 MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE FIMBRION THERAPEUTICS, INC. 2022-07-28 US disclosed
US-20210122776-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-04-29 US disclosed
US-20200407390-A1 MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE FIMBRION THERAPEUTICS INC (US) 2020-12-31 US disclosed
US-10738070-B2 Mannose-derived antagonists of FimH useful for treating disease FIMBRION THERAPEUTICS, INC. (US) 2020-08-11 US disclosed
WO-2014194270-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS WASHINGTON UNIVERSITY (US) 2014-12-04 WO disclosed
US-20120309701-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS THE WASHINGTON UNIVERSITY (US) 2012-12-06 US disclosed
US-20120309701-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS THE WASHINGTON UNIVERSITY (US) 2012-12-06 US disclosed
EP-2305671-A1 Thiophene and thiazole derivatives as CHK1 inhibitors AstraZeneca AB (SE) 2011-04-06 EP disclosed
EP-1732920-B1 THIOPHENE DERIVATIVES AS CHK 1 INHIBITORS ASTRAZENECA AB (SE) 2011-03-09 EP disclosed
CN-100584840-C Substituted heterocyclic compounds and uses thereof ASTRAZENECA AB 2010-01-27 CN disclosed
CN-1922172-A Substituted heterocyclic compounds and uses thereof ASTRAZENECA AB (SE) 2007-02-28 CN disclosed
US-20070010556-A1 Thiophene derivatives as chk 1 inhibitors ASTRAZENECA AB (SE) 2007-01-11 US disclosed
EP-1732920-A2 THIOPHENE DERIVATIVES AS CHK 1 INHIBITORS AstraZeneca AB (SE) 2006-12-20 EP disclosed
WO-2005066163-A2 THIOPHENE DERIVATIVES AS CHK 1 INIHIBITORS ASTRAZENECA AB (SE) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230033327-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS FPR1, VIL1, VIP MAPT 955/4885KDM4E 4317/4885ALDH1A1 526/4885
US-20250009723-A1 MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE MAN2B2, MAN2A1, MANBA MAPT 2578/4885KDM4E 4648/4885ALDH1A1 1880/4885
US-20120309701-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS MMP8, ELANE, GUSB MAPT 2205/4885KDM4E 3809/4885ALDH1A1 519/4885
US-20200407390-A1 MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE MAN2B2, MAN2A1, MANBA MAPT 2578/4885KDM4E 4648/4885ALDH1A1 1880/4885
US-20070010556-A1 Thiophene derivatives as chk 1 inhibitors CHEK1, CHKA, CHEK2 MAPT 3514/4885KDM4E 713/4885ALDH1A1 2326/4885
US-20220235087-A1 MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE MAN2B2, MAN2A1, MANBA MAPT 2578/4885KDM4E 4648/4885ALDH1A1 1880/4885
US-20210122776-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS FPR1, VIL1, VIP MAPT 955/4885KDM4E 4317/4885ALDH1A1 526/4885
US-10738070-B2 Mannose-derived antagonists of FimH useful for treating disease MAN2B2, MAN2A1, MANBA MAPT 2578/4885KDM4E 4648/4885ALDH1A1 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.